Loading organizations...
Based in Helsinki, Finland, Avenue Biosciences develops AI-enhanced protein engineering technology to accelerate and optimize therapeutic protein production for the global biopharmaceutical industry. The company utilizes machine learning to measure and modulate the cellular secretory pathway at scale, allowing drug manufacturers to screen 5,000 to 6,000 signal peptide variants in parallel during single experiments. This proprietary platform is licensed to biopharmaceutical manufacturers to improve the manufacturing efficiency and yield of complex biologics, including monoclonal antibodies, mRNA vaccines, and gene therapies. Avenue Biosciences has raised $8.7 million in total funding to date across multiple rounds, supported by prominent venture capital investors such as Voima Ventures, Inventure, Balnord, and Tesi. The venture-backed biotechnology firm was officially founded in 2023 as a spin-out from the University of Helsinki by Tero-Pekka Alastalo, Ville Paavilainen, Katja Rosti, and Juho Kellosalo.
Avenue Biosciences has raised $8.7M across 2 funding rounds.
Avenue Biosciences has raised $8.7M in total across 2 funding rounds.
Avenue Biosciences has raised $8.7M across 2 funding rounds. Most recently, it raised $5.7M Seed Extension in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $5.7M Seed Plus | Gabrielė Poteliūnaitė, Miia Kaye | Dimerent, Inventure, University OF Helsinki Funds, Voima Ventures | Announced |
| Oct 1, 2024 | $3M Seed | Jenny Engerfelt | Inventure, Jaan Tallinn | Announced |
Avenue Biosciences has raised $8.7M in total across 2 funding rounds.
Avenue Biosciences's investors include Gabrielė Poteliūnaitė, Miia Kaye, Dimerent, Inventure, University of Helsinki Funds, Voima Ventures, Jenny Engerfelt, Jaan Tallinn.
Avenue Biosciences is a biotechnology company that develops a proprietary protein engineering platform combining high-throughput chemistry and machine learning to significantly enhance protein expression yields—by up to 500%—especially for difficult-to-express proteins. This technology accelerates the development of protein biologics, mRNA therapies, vaccines, and biosimilars by overcoming production barriers that traditionally slow therapeutic development and increase costs. Their primary customers are biopharmaceutical companies, biotech firms, and research institutions focused on protein-based therapeutics. Founded in 2023 and headquartered in Palo Alto, Avenue Biosciences has raised over $2.5 million in seed funding and operates with a team of about 10 employees[1][2][3].
The company originated as a spinout from the University of Helsinki, based on fundamental cell biology research led by Dr. Ville Paavilainen at the Institute of Biotechnology. The founding team includes CEO Tero-Pekka Alastalo, CSO Juho Kellosalo, and COO Katja Rosti, all with strong scientific backgrounds. The idea emerged from the discovery that analyzing thousands of natural and synthetic signal peptides could identify those that maximize protein production, a critical bottleneck in biologic drug development. Early traction included successful external validations demonstrating up to 500% yield improvements and seed investments from Helsinki University Funds and Voima Ventures, enabling expansion into both European and U.S. markets[4][5].
Avenue Biosciences is positioned at the intersection of biotechnology, synthetic biology, and artificial intelligence, riding the wave of AI-driven innovation in protein biologics. The timing is critical as the global biologics market expands rapidly, with many top-selling biologics losing exclusivity and a growing demand for cost-efficient biosimilars and novel therapies. Their platform addresses a fundamental bottleneck in therapeutic protein production, enabling faster, more scalable, and cost-effective drug development. This not only accelerates innovation but also helps ensure that life-saving therapies are not delayed or abandoned due to manufacturing challenges. By integrating AI and high-throughput methods, Avenue Biosciences contributes to the broader ecosystem by providing tools that enhance the efficiency and success rate of biologic drug discovery and development[3][4].
Looking ahead, Avenue Biosciences is poised for significant growth as it scales its technology across global markets, with a key catalyst expected around late 2025. Trends such as AI integration in biotech, increasing demand for biosimilars, and the expansion of mRNA therapeutics will shape their trajectory. Their influence is likely to grow as they enable biopharmaceutical companies to overcome production barriers more efficiently, potentially becoming a critical partner in the biologics supply chain. Continued innovation in machine learning models and expansion of their signal peptide libraries could further enhance their platform’s capabilities, solidifying their role as a transformative player in protein biologics development[2][3][5].
